LGX818 + MEK162 + LEE011
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors Harboring a BRAF V600 Mutation
Conditions
Solid Tumors Harboring a BRAF V600 Mutation
Trial Timeline
May 28, 2012 → Mar 9, 2023
NCT ID
NCT01543698About LGX818 + MEK162 + LEE011
LGX818 + MEK162 + LEE011 is a phase 1/2 stage product being developed by Pfizer for Solid Tumors Harboring a BRAF V600 Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT01543698. Target conditions include Solid Tumors Harboring a BRAF V600 Mutation.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01543698 | Phase 1/2 | Completed |
Competing Products
20 competing products in Solid Tumors Harboring a BRAF V600 Mutation